千红制药：8月13日召开董事会会议

Group 1 - The core point of the article is that Qianhong Pharmaceutical announced the convening of its sixth board meeting to discuss a settlement agreement with Jianyuan Trust [1] - For the year 2024, Qianhong Pharmaceutical's revenue composition is 99.75% from the biopharmaceutical industry and 0.25% from other sources [1] - As of the report date, Qianhong Pharmaceutical has a market capitalization of 12.9 billion yuan [1] Group 2 - A separate investigation into sunscreen products reveals that while production costs are around 3 yuan, retail prices can reach several tens of yuan, indicating significant profit margins in the industry [1] - The factory owner mentioned that the profit margins in this industry are substantial, with several times the cost being considered a low profit [1]